Cargando…
Oligometastatic state predicts a favorable outcome for renal cell carcinoma patients with bone metastasis under the treatment of sunitinib
BACKGROUND: The aim of the study was to investigate whether RCC patients with oligometastatic state of bone metastasis treated with sunitinib had a favorable clinical outcome. RESULTS: 22 patients were classified into oligometastatic state of bone metastasis with a median OS of 30.1 months (95%CI: 2...
Autores principales: | Lu, Xiaolin, Gu, Weijie, Zhang, Hailiang, Zhu, Yao, Shi, Guohai, Ye, Dingwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042022/ https://www.ncbi.nlm.nih.gov/pubmed/27058898 http://dx.doi.org/10.18632/oncotarget.8568 |
Ejemplares similares
-
Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma
por: Lu, Xiaolin, et al.
Publicado: (2021) -
Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients
por: Gu, Weijie, et al.
Publicado: (2017) -
Prognostic Value of Components of Body Composition in Patients Treated with Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Case Series
por: Gu, Weijie, et al.
Publicado: (2015) -
Nutritional screening is strongly associated with overall survival in patients treated with targeted agents for metastatic renal cell carcinoma
por: Gu, Weijie, et al.
Publicado: (2015) -
Construction and Validation of a 9-Gene Signature for Predicting Prognosis in Stage III Clear Cell Renal Cell Carcinoma
por: Wu, Junlong, et al.
Publicado: (2019)